Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that key executives will participate in the Goldman Sachs Leveraged Finance Conference on June 25, 2020, at 11:25 a.m. EDT. The executives include Paul S. Herendeen, Arthur J. Shannon, and William Woodfield. A live webcast and audio archive will be available on the company’s Investor Relations page. Bausch Health aims to enhance lives through its diverse healthcare products, focusing on eye health, gastroenterology, and dermatology.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the inaugural Salix Gastrointestinal Health Scholars Program, awarding scholarships to ten students living with gastrointestinal diseases. Each recipient will receive $10,000 to support their education. The selection was based on over 100 applications, with an independent panel reviewing essays that highlighted the challenges faced by applicants and the support received from healthcare professionals. The program aims to recognize students' resilience in pursuing academic achievements despite their health challenges.